Furthermore, combinatorial administration of letrozole with PD-1/PD-L1 blockade agents demonstrates synergistic efficacy, offering a promising strategy for optimizing immunotherapy outcomes, especially in 17-β-estradiol/ERα high female NSCLC patients (64). The gene discussed is CD274; the disease is non-small cell lung carcinoma.